We next performed immunohistochemical analysis of biopsies from 54 patients with genetically diverse metastatic melanoma and confirmed high expression of BRD4 in NRASMut tumors; BRD4 levels were markedly higher than in tumors harboring mutant BRAF or wild‐type for BRAF and NRAS (WT) (Fig 1B and C). This evidence concerns the gene BRD4 and metastatic melanoma.